326 related articles for article (PubMed ID: 11481596)
21. Institutional review boards (IRBs) and reproductive medicine: guidelines for compliance.
Cackowski A
J Health Hosp Law; 1996; 29(2):121-4. PubMed ID: 10160175
[No Abstract] [Full Text] [Related]
22. Potential liability for institutional review boards and bioethics committees.
Reider A
Home Care Econ; 1987; 1(4):119-21. PubMed ID: 10285379
[No Abstract] [Full Text] [Related]
23. Evolution of the role of an applied bioethicist in a research hospital.
Fletcher JC; Boverman M
Prog Clin Biol Res; 1983; 128():131-58. PubMed ID: 6634727
[TBL] [Abstract][Full Text] [Related]
24. The HIPAA privacy rule: practical advice for academic and research institutions.
Gunter KP
Healthc Financ Manage; 2002 Feb; 56(2):50-4. PubMed ID: 11842502
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of human subjects protection at CDC/ATSDR.
Santelli J; Ginn E; Speers MA
IRB; 2000; 22(4):1-7. PubMed ID: 11883474
[No Abstract] [Full Text] [Related]
26. [Ethics. What remains of respect for man?].
Rosenkvist I
Sygeplejersken; 1984 Jul; 84(29):8-11. PubMed ID: 6567341
[No Abstract] [Full Text] [Related]
27. Policy advice for Congress.
Prot Hum Subj; 2000; ():5-6. PubMed ID: 12564439
[No Abstract] [Full Text] [Related]
28. Guide to decision-making in institutional review of proposals for human experimentation: commentary.
George R
Man Med; 1978; 3(3):210-2. PubMed ID: 10316737
[No Abstract] [Full Text] [Related]
29. Final regulations amending basic HHS policy for the protection of human research subjects--Department of Health and Human Services. Final rule.
Fed Regist; 1981 Jan; 46(16 Pt 2):8366-91. PubMed ID: 10249932
[TBL] [Abstract][Full Text] [Related]
30. United States regulatory requirements for research involving human subjects.
J Biolaw Bus; 1998; 1(2):39-53. PubMed ID: 12739542
[No Abstract] [Full Text] [Related]
31. Position statement of the AFCR on FDA proposal to assign scientific review of new drugs for human use to local institutional review boards.
American Federation for Clinical Research
Clin Res; 1982 Feb; 30(1):27-8. PubMed ID: 11653562
[No Abstract] [Full Text] [Related]
32. Protecting "human guinea pigs".
Thompson RC
FDA Consum; 1986 Dec-1987 Jan; 20(10):12-5. PubMed ID: 10311766
[No Abstract] [Full Text] [Related]
33. Tightening the screws on human subjects protection.
Tilden V
Nurs Res; 2001; 50(4):193. PubMed ID: 11480527
[No Abstract] [Full Text] [Related]
34. Tales of informed consent: four years on an institutional review board.
Bartolo
Health Matrix Clevel; 1992; 2(2):193-245. PubMed ID: 10124879
[No Abstract] [Full Text] [Related]
35. The new RAC: restructuring of the National Institutes of Health recombinant DNA Advisory Committee.
Beach JE
Food Drug Law J; 1999; 54(1):49-53. PubMed ID: 11758560
[No Abstract] [Full Text] [Related]
36. Program profile: continuum of care committee eases network merger pains.
Kernaghan SG
Continuum; 1997; 17(4):18-20. PubMed ID: 10173863
[No Abstract] [Full Text] [Related]
37. Achieving proper balance in research with decisionally-incapacitated subjects: NAMI's perspectives on the working group's proposal.
Flynn LM; Honberg RS
J Health Care Law Policy; 1998; 1(1):174-92. PubMed ID: 15573436
[No Abstract] [Full Text] [Related]
38. Institutional review boards and the freedom to take risks.
Pattullo EL
N Engl J Med; 1982 Oct; 307(18):1156-9. PubMed ID: 7121543
[No Abstract] [Full Text] [Related]
39. New guidelines for institutional review boards stress special role.
Maloney DM
Hum Res Rep; 2000 Dec; 15(12):1-2. PubMed ID: 11789516
[No Abstract] [Full Text] [Related]
40. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
Weijer C
IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
